Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy

Inclusion Criteria

• •Male or female subjects aged 18 years or older at the time of informed consent
• •Diagnosis of atopic dermatitis (AD) for at least 1 year and current status of moderate to severe disease (\>= the following scores: BSA 10%, IGA 3, EASI 16, Pruritus NRS severity 4)
• •Documented recent history (within 6 months before the screening visit) of inadequate response to treatment with medicated topical therapy for AD for at least 4 weeks, or who have required systemic therapies for control of their disease.
• •Must be willing and able to comply with standardized background topical therapy, as per protocol guidelines throughout the study
• •Female subjects who are of childbearing potential must not be intending to become pregnant, currently pregnant, or lactating. The following conditions apply:
• •1. Female subjects of childbearing potential must have a confirmed negative pregnancy test prior to randomization;
• •2. Female subjects of childbearing potential must agree to use a highly effective method of contraception for the duration of the active treatment period and for at least 28 days after the last dose of investigational product.
• •Female subjects of non-childbearing potential must meet at least 1 of the following criteria:
• •* Have undergone a documented hysterectomy and/or bilateral oophorectomy;
• •* Have medically confirmed ovarian failure; or
• •* Achieved postmenopausal status, defined as follows: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause and have a serum follicle stimulating hormone (FSH) level confirming the postmenopausal state.
• •All other female subjects (including female subjects with tubal ligations) are considered to be of childbearing potential.
• •If receiving concomitant medications for any reason other than AD, must be on a stable regimen prior to Day 1 and through the duration of the study